Calcemin tablets, No. 60

• Prevention and complex treatment of osteoporosis of various origins;

• replenishment of calcium and trace element deficiency in children and adolescents;

• replenishment of calcium and trace element deficiency in women during pregnancy and during breastfeeding.

Inside.

Children from 5 to 12 years old - 1 table. 1 time per day with meals.

Adults and children over 12 years old - 1 tab. 2 times a day with meals.

During pregnancy and breastfeeding: from the 20th week of pregnancy and the entire period of breastfeeding - 1 tab. 2 times a day.

The minimum course of taking the drug for the treatment of osteoporosis as part of complex therapy for adults is 3 months, a longer course - after consulting a doctor.

The minimum course of taking the drug for the prevention of osteoporosis for adults is 1 month, a longer course - after consulting a doctor.

The minimum course of taking the drug for children and adults with a deficiency of calcium and trace elements is 2-3 months, a longer course - after consulting a doctor.

A repeated course of taking the drug is possible 1 month after the end of treatment.

Film-coated tablets, white, oval, biconvex, with a line on one side.

1 tab.

calcium (in the form of calcium citrate tetrahydrate and calcium carbonate) 250 mg

colecalciferol (vit. D3) 50 IU

zinc (in the form of zinc oxide) 2 mg

copper (in the form of copper oxide) 500 mcg

manganese (in the form of manganese sulfate) 500 mcg

boron (in the form of sodium borate decahydrate) 50 mcg

Excipients: soy polysaccharide - 10 mg, sodium lauryl sulfate - 5 mg, colloidal silicon dioxide - 3.9 mg, sodium croscarmellose - 28 mg, microcrystalline cellulose - 199.45 mg, stearic acid - 35 mg, magnesium stearate - 10 mg.

• Increased individual sensitivity to any of the components of the drug;

• hypercalcemia and hypercalciuria;

• nephrolithiasis;

• hypervitaminosis D3;

• severe renal failure;

• active form of tuberculosis;

• decalcifying tumors (myeloma, bone metastases, sarcoidosis);

• children under 5 years of age.

Precautions: benign granulomatosis; taking cardiac glycosides and thiazide diuretics; pregnancy; lactation period.

pharmachologic effect

Combined preparation containing calcium, vitamin D3, osteotropic minerals that regulate calcium metabolism. The pharmacological action of the drug is determined by the properties of its constituent components.

Calcium is involved in the formation of bone tissue, reduces resorption and increases bone density, prevents diseases of the musculoskeletal system, helps to strengthen bone tissue and joints. Calcium citrate ensures the absorption of calcium, regardless of the functional state of the gastrointestinal tract, which is applicable for the treatment of patients with reduced secretory function of the gastrointestinal tract, as well as during treatment with drugs to reduce secretion; reduces the level of markers of bone resorption, which indicates a slowdown in the processes of destruction of bone tissue; regulates the content of parathyroid hormone, which leads to improved regulation of calcium homeostasis; does not increase the content of oxalates and calcium in the urine, therefore does not cause the formation of kidney stones; does not block the absorption of iron, which reduces the risk of developing iron deficiency anemia.

Colecalciferol (vitamin D3) regulates the exchange of calcium and phosphorus in the body, participates in the formation of the bone skeleton, helps preserve the structure of bones, enhances calcium absorption in the intestine and reabsorption of phosphorus in the renal tubules.

Zinc promotes the synthesis of sex hormones, which prevents the destruction of bone tissue.

Manganese is involved in the formation of proteoglycans, which improves the quality of bone tissue and forms the protein matrix of bone tissue.

Copper is involved in the synthesis of collagen and elastin, which is part of bone and connective tissue, which affects the formation of bone mass.

Boron reduces the excessive activity of parathyroid hormone, improves calcium absorption, reduces the risk of developing cholecalciferol deficiency, and helps prevent osteoporosis.

Side effect

From the digestive system: nausea, vomiting, flatulence, diarrhea, constipation.

From the side of metabolism: hypercalcemia and hypercalciuria.

Allergic reactions: itching, rash, urticaria.

Application during pregnancy and lactation

During pregnancy and lactation, the use of the drug should be agreed with your doctor.

The daily dose should not exceed 1500 mg of calcium and 600 IU of vitamin D3. Hypercalcemia, which develops against the background of an overdose of the drug during pregnancy, can cause defects in mental and physical development in the fetus.

In lactating women, it should be taken into account that cholecalciferol and its metabolites are excreted in breast milk, therefore, the intake of calcium and vitamin D3 from other sources should be taken into account.

Application for impaired renal function

The use of the drug is contraindicated in severe renal failure and nephrolithiasis.

Application in children

The use of the drug in children under 5 years of age is contraindicated.

special instructions

When using the drug, the recommended dose should not be exceeded. increased calcium intake can inhibit intestinal absorption of iron, zinc and other essential minerals.

Influence on the ability to drive vehicles and mechanisms

Does not affect.

Overdose

In case of an overdose of the drug, the development of hypervitaminosis D, hypercalcemia and hypercalciuria is possible.

Symptoms: decreased appetite, thirst, polyuria, dizziness, fainting, constipation, nausea and vomiting. With long-term use in high doses - calcification of blood vessels and tissues.

Treatment: it is necessary to reduce the dose or stop using the drug. In case of accidental overdose, induce vomiting, rinse the stomach. Conducting symptomatic therapy is shown.

Drug interactions

With the simultaneous use of the drug CalceminЃ with vitamin A, the toxicity of vitamin D3 decreases.

Phenytoin, barbiturates, glucocorticoids reduce the effectiveness of vitamin D3.

Laxatives reduce the absorption of vitamin D3.

Glucocorticoids, hormonal contraceptives for systemic use, levothyroxine impair the absorption of calcium ions.

With simultaneous use with tetracycline, the interval between doses should be at least 3 hours, with bisphosphonates and sodium fluoride - at least 2 hours (their absorption is impaired).

With the combined use of the drug CalceminЃ with cardiac glycosides, the toxicity of the latter increases (monitoring of the ECG and clinical condition is necessary).

With simultaneous use with thiazide diuretics, the risk of developing hypercalcemia increases, with furosemide and other 'loop' diuretics - the excretion of calcium by the kidneys increases.

CalceminЃ should not be used concurrently with calcium channel blockers.

The simultaneous use of the drug with antacids that contain aluminum is not recommended, due to a decrease in their effectiveness.